Global Biochip Markets, 2016-2020 & 2021-2026: Drug Discovery & Development, Disease Diagnostics, Genomics, Others

Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Global Biochip Market By Type (DNA Chips, Lab-On-a-Chips & Protein Chips), By Technology (Microarray v/s Microfluidics), By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Others), By End User, By Company, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

The Global Biochip Market is expected to grow at an impressive rate of around 15% during the forecast period.

The Global Biochip Market is driven by the growing prevalence of various chronic and infectious disease especially in the geriatric population who are more susceptible to these diseases on account of low immunity. This has led to the increase in the demand for personalized medicine solutions or targeted therapies especially for treating diseases like cancer. This in turn is expected to positively influence the market growth over the next few years.

Additionally, increasing R&D activities and supportive government policies further propel the market. Furthermore, ongoing technological innovations and new product launches by the major players operating in the market is expected to create lucrative opportunities for market growth through 2026.

However, high cost of biochips can hamper the market growth. Moreover, lack of awareness especially in the developing and underdeveloped world further impedes market growth. Besides, strict regulatory regulations imposed by the different governments across the globe further restrict the market growth during forecast period.

The Global Biochip Market is segmented based on type, technology, application, end-user, company, and region. Based on type, the market can be categorized into DNA chips, lab-on-a-chips and protein chips. The DNA chips segment is expected to dominate the market on account of its widespread adoption and use. Based on technology, the market can be bifurcated into microarray and microfluidics.

The microarray technology is expected to dominate the market on account of its extensive use in forensic analysis and identification of drug candidates in drug discovery process. While, the microfluidics technology is expected to grow significantly on account of the increasing use of point of care diagnostic devices such as pregnancy kits, cardiac makers, blood gases, among others.

Based on end-user, the market can be fragmented into biotechnology & pharmaceutical companies, hospitals & diagnostics centers, academic & research institutes and others. The hospitals & diagnostic centers segment is expected to dominate the market on account of the extensive use of biochips by them. This can be ascribed to the associated advantages of biochips such as affordability, time saving and ability of delivering high throughput without requiring instruments.

Regionally, the Biochip market has been segmented into various regions including Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the market on account of the growing prevalence of various sedentary lifestyle associated diseases in the country.

While, the Asia Pacific region is expected to register the highest growth through 2026. This can be ascribed to the growth in the Life science industry in the industry. Additionally, major players operating in the market are expanding their business in the region especially in countries like India and China.

The major players operating in the biochip market are Abbott Laboratories, Agilent Technologies, Inc., PerkinElmer Inc., Fluidigm Corporation, Illumina, Inc., GE Healthcare, Bio-Rad Laboratories Inc., Cepheid Inc., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, bioMerieux SA, Horiba, Ltd., Qiagen N.V., Randox Laboratories Ltd., OriGene Technologies, Inc., Dynamic Biosensors GmbH, General Electric Company, Genalyte, Inc., Hologic, Inc., Arbor Biosciences and others.

Major companies are developing advanced technologies and launching new services in order to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Key Target Audience:

• Biochip manufacturers/suppliers/distributors

• Market research and consulting firms

• Government bodies such as regulating authorities and policy makers

• Organizations, forums and alliances related to biochip

Years considered for this report:

• Historical Year: 2016-2019

• Base Year: 2020 Estimated Year: 2021
  Forecast Period: 2022-2026

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Biochip Market

4. Executive Summary

5. Voice of Customer

6. Global Biochip Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type (DNA Chips, Lab-On-a-Chips, Protein Chips)
6.2.2. By Technology (Microarray v/s Microfluidics)
6.2.3. By Application (Drug Discovery & Development, Disease Diagnostics, Genomics, Proteomics, Agriculture, Others)
6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Hospitals & Diagnostics Centers, Academic & Research Institutes, Others)
6.2.5. By Company (2020)
6.2.6. By Region
6.3. Product Market Map

7. Asia-Pacific Biochip Market Outlook

8. Europe Biochip Market Outlook

9. North America Biochip Market Outlook

10. South America Biochip Market Outlook

11. Middle East and Africa Biochip Market Outlook

12. Market Dynamics
12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape
14.1. Abbott Laboratories
14.2. Agilent Technologies, Inc.
14.3. PerkinElmer Inc.
14.4. Fluidigm Corporation
14.5. Illumina, Inc.
14.6. GE Healthcare
14.7. Bio-Rad Laboratories Inc.
14.8. Cepheid Inc.
14.9. Thermo Fisher Scientific, Inc.
14.10. F. Hoffmann-La Roche AG
14.11. bioMerieux SA
14.12. Horiba, Ltd.
14.13. Qiagen N.V.
14.14. Randox Laboratories Ltd.
14.15. OriGene Technologies, Inc.
14.16. Dynamic Biosensors GmbH
14.17. General Electric Company
14.18. Genalyte, Inc.
14.19. Hologic, Inc.
14.20. Arbor Biosciences

15. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/8tkz1u

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900